January 11, 2021
TriStar Health is now offering Bamlanivimab antibody infusions to non-hospitalized patients who have tested positive for COVID-19 and have other high-risk factors. The treatment is being administered at TriStar Southern Hills Medical Center in Nashville and at TriStar StoneCrest Medical Center in Smyrna.
The U.S. Food & Drug Administration (FDA) granted Emergency Use Authorizations (EUA) of Bamlanivimab for the treatment of COVID-19 in patients experiencing mild to moderate symptoms who are high-risk to develop severe COVID-10. The drug is administered through outpatient IV infusion for adults and adolescents age 12 and older.
High-risk conditions that may be eligible for this treatment include:
- Chronic Kidney Disease
- Immunosuppressive Disorder
- Heart Disease
For children over the age of 12, sickle cell disease, neurodevelopmental disorders and asthma are also among several additional considerations for eligibility.
Medication supply is limited and administered based upon availability. Patients must have a physician referral and meet eligibility requirements to be considered for the treatment. The outpatient infusion is given over the course of one hour, followed by an additional hour of observation.
Bamlanvimab is not authorized for patients who:
- Are hospitalized due to COVID-19
- Require oxygen therapy due to COVID-19
- Require oxygen due to another underlying medical condition
If you have recently tested positive for COVID-19 and are interested in this treatment, please reach out to your primary care physician or call TriStar Medline at (615) 342-1919 for more information.
TriStar Southern Hills Medical Center is offering treatment appointments Monday – Friday from 7:00 a.m. – 12:30 p.m.
TriStar StoneCrest Medical Center is offering treatment appointments at 3 p.m. on Tuesdays and Wednesdays.